Godavari Drugs Ltd

Godavari Drugs has reached a new 52-week low of Rs.73.2, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its ongoing price decline. The stock’s performance over the past year reflects a challenging period for the company within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its ongoing price decline. This development reflects a continuation of the stock’s subdued performance over the past year, contrasting with broader market gains.

Godavari Drugs has reached a new 52-week low of Rs.74, marking a significant milestone in its recent price movement. This decline reflects ongoing pressures on the stock within the Pharmaceuticals & Biotechnology sector, as it trades below all key moving averages amid broader market gains.

Godavari Drugs has reached a new 52-week low of Rs.75.2, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges over the past year.

Godavari Drugs has reached a new 52-week low, with its share price touching Rs.75.45 today. This marks a significant decline for the pharmaceutical company amid broader market fluctuations and sectoral pressures.

Godavari Drugs has reached a new 52-week low of Rs.77.01 today, marking a significant decline amid a sustained downward trajectory over recent sessions. The stock’s performance contrasts sharply with broader market trends, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Godavari Drugs, a player in the Pharmaceuticals & Biotechnology sector, touched a fresh 52-week low of Rs.77.01 today, marking a significant milestone in its recent price movement. The stock has been on a declining trajectory over the past three sessions, reflecting a cumulative return of -7.1% during this period.

Godavari Drugs has reached a new 52-week low of Rs.78.06 today, marking a significant decline as the stock continues to trade below all key moving averages amid a challenging market environment.

Godavari Drugs has reached a new 52-week low of Rs.78.06 today, marking a significant point in its recent price trajectory as the stock continues to trade below all major moving averages amid a challenging market environment.

Godavari Drugs, a player in the Pharmaceuticals & Biotechnology sector, touched a new 52-week low of Rs.78.25 on 19 Nov 2025, marking a significant decline in its stock price amid ongoing subdued financial performance and market pressures.

Godavari Drugs Ltd., a Nanded-based manufacturer of active pharmaceutical ingredients (APIs) and drug intermediates, reported a net profit of ₹1.00 crore for Q2 FY26, marking a modest sequential decline of 3.85% from ₹1.04 crores in Q1 FY26, whilst registering a sharp year-on-year contraction of 8.26% from ₹1.09 crores in Q2 FY25. With a market capitalisation of just ₹62.00 crores, this micro-cap pharmaceutical player continues to grapple with margin pressures and tepid revenue growth, raising serious concerns about its ability to navigate an increasingly competitive API landscape.

Godavari Drugs has reached a new 52-week low, continuing a trend of declining stock prices over six consecutive days. Despite a slight intraday gain, the stock remains below key moving averages and has seen a significant year-over-year decline, raising concerns about its financial health and performance.

Godavari Drugs has reached a new 52-week low, continuing a trend of declining prices over six consecutive days. Despite a brief intraday increase, the stock closed lower and is trading below multiple moving averages. The company has faced challenges, including negative quarterly results and a high Debt to EBITDA ratio.

Godavari Drugs has reached a new 52-week low of Rs. 78.3, reflecting a 33.76% decline over the past year. The stock has faced six consecutive days of decline, despite a slight recovery today. Financial concerns include a high Debt to EBITDA ratio and negative results for three quarters.

Godavari Drugs has hit a new 52-week low, reflecting a 34.35% decline over the past year, contrasting with the Sensex's slight gain. The company has reported negative financial results for three consecutive quarters and faces concerns regarding its debt servicing capabilities, despite trading at a discount to peers.

Godavari Drugs has hit a new 52-week low, reflecting a significant decline of 34.35% over the past year, contrasting with the Sensex's modest gain. The stock is trading below key moving averages, and the company faces financial challenges, including a high Debt to EBITDA ratio and declining profits.